for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.AS

Latest Trade

141.70EUR

Change

-6.00(-4.06%)

Volume

560,508

Today's Range

141.70

 - 

147.00

52 Week Range

74.48

 - 

171.20

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Hitgen Enters Into Dna-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV

Oct 16 (Reuters) - HITGEN INC <HitGen Inc>::HITGEN ENTERS INTO DNA-ENCODED LIBRARY BASED DRUG DISCOVERY RESEARCH COLLABORATION WITH GALAPAGOS NV.HITGEN SAYS WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND WILL BE ELIGIBLE FOR MILESTONE PAYMENTS FROM GALAPAGOS NV.

Galapagos Increases Share Capital Through Warrant Exercises

Sept 20 (Reuters) - GALAPAGOS NV <GLPG.AS>::ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN.EXECUTIVE COMMITTEE MEMBERS AUTOMATICALLY ARE COMMITTED TO EXERCISE A MINIMUM NUMBER OF WARRANTS.CEO ONNO VAN DE STOLPE EXERCISED 15,000 WARRANTS.3 OTHER EXECUTIVE COMMITTEE MEMBERS EXERCISED AN AGGREGATE 107,500 WARRANTS AND A MEMBER OF BOARD OF DIRECTORS EXERCISED 20,400 WARRANTS.TOTAL SHARE CAPITAL CURRENTLY AMOUNTS TO EUR 335.1 MLN, 61.9 MLN SECURITIES WITH VOTING RIGHTS.

Pharnext Updates On Collaboration with Galapagos

Sept 9 (Reuters) - PHARNEXT SA <PHARN.PA>::PHARNEXT AND GALAPAGOS SUCCESSFULLY ACHIEVED THEIR RESEARCH AND DEVELOPMENT COLLABORATION.COLLABORATION AIMS TO GENERATE A NEW DRUG DEVELOPMENT PIPELINE IN SEVERAL THERAPEUTIC AREAS FOR GALAPAGOS.COLLABORATION HAS LED TO IDENTIFICATION OF INTERESTING NOVEL COMBINATIONS THAT ARE NOW IN ADVANCED PRECLINICAL TESTING.

Galapagos Files Application To Initiate Insolvency Proceedings

Aug 25 (Reuters) - Galapagos NV <GLPG.AS>::GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS.GALAPAGOS-BY WAY OF ORDER OF 23 AUGUST 2019 LOCAL COURT OF DÜSSELDORF APPOINTED FRANK KEBEKUS AS PRELIMINARY INSOLVENCY ADMINISTRATOR OF ASSETS OF CO.GALAPAGOS-NO ENFORCEMENT OVER SHARES IN & PREFERRED EQUITY CERTIFICATES OF GALAPAGOS BIDCO MAY OCCUR DURATION OF PRELIMINARY INSOLVENCY PROCEEDINGS.GALAPAGOS-ALSO ANNOUNCES IT NO LONGER ENVISAGES IMPLEMENTING TRANSACTION PREVIOUSLY ANNOUNCED & AS DEFINED IN, CO'S ANNOUNCEMENT ON 7 JUNE 2019.COMPANY WITHDREW ITS INSTRUCTIONS TO ITS COUNSEL TO PROCEED WITH APPLICATION IN ENGLISH HIGH COURT.CO OPPOSED MAKING OF ANY ADMINISTRATIVE ORDER IN ENGLISH HIGH COURT.GALAPAGOS - DISMISSED MATTHEW CHARLES TURNER, AND JOHN SAMUEL KEEN, AS DIRECTORS WITH EFFECT AS OF DATE HEREOF.APPOINTED JAN BAYER AS SOLE DIRECTOR OF COMPANY, WITH EFFECT AS OF DATE HEREOF.

BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

Corrects throughout to show the alerts were from Galapagos SA, not from Galapagos NV <GLPG.AS>:GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS.GALAPAGOS-BY WAY OF ORDER OF 23 AUGUST 2019 LOCAL COURT OF DÜSSELDORF APPOINTED FRANK KEBEKUS AS PRELIMINARY INSOLVENCY ADMINISTRATOR OF ASSETS OF CO.GALAPAGOS-NO ENFORCEMENT OVER SHARES IN & PREFERRED EQUITY CERTIFICATES OF GALAPAGOS BIDCO MAY OCCUR DURATION OF PRELIMINARY INSOLVENCY PROCEEDINGS.GALAPAGOS-ALSO ANNOUNCES IT NO LONGER ENVISAGES IMPLEMENTING TRANSACTION PREVIOUSLY ANNOUNCED & AS DEFINED IN, CO'S ANNOUNCEMENT ON 7 JUNE 2019.COMPANY WITHDREW ITS INSTRUCTIONS TO ITS COUNSEL TO PROCEED WITH APPLICATION IN ENGLISH HIGH COURT.CO OPPOSED MAKING OF ANY ADMINISTRATIVE ORDER IN ENGLISH HIGH COURT.GALAPAGOS - DISMISSED MATTHEW CHARLES TURNER, AND JOHN SAMUEL KEEN, AS DIRECTORS WITH EFFECT AS OF DATE HEREOF.APPOINTED JAN BAYER AS SOLE DIRECTOR OF COMPANY, WITH EFFECT AS OF DATE HEREOF.

Galapagos Says H1 Loss Per Share Eur 1.76

July 25 (Reuters) - Galapagos NV <GLPG.AS>::H1 LOSS PER SHARE EUR 1.76 .STRONG CLINICAL PROGRESS IN H1 AND TRANSFORMATIVE COLLABORATION WITH GILEAD ANNOUNCED.H1 OPERATING LOSS OF EUR 97.6 MILLION.SAYS H1 REVENUES EUR 108.5MLN VERSUS EUR 101.9 MILLION.FINANCIAL GUIDANCE FOR FULL YEAR 2019 OPERATIONAL CASH BURN BETWEEN EUR 320 AND EUR 340 MILLION IS UNCHANGED.GILEAD INTENDS TO FILE FILGOTINIB FOR APPROVAL IN RA IN EUROPE IN Q3 2019.H1 OPERATING LOSS 97.6 MILLION EUROS VERSUS LOSS OF 65.8 MILLION EUROS.H1 NET FINANCIAL RESULT 1.8 MILLION EUROS VERSUS 6.9 MILLION EUROS.

Proteostasis Therapeutics Announces Management Changes And Appointments

July 23 (Reuters) - Proteostasis Therapeutics Inc <PTI.O>::PROTEOSTASIS THERAPEUTICS ANNOUNCES MANAGEMENT CHANGES AND APPOINTMENTS.PROTEOSTASIS THERAPEUTICS INC - GEOFFREY S. GILMARTIN, MD, MMSC, TO SUCCEED PO-SHUN LEE, MD AS CHIEF MEDICAL OFFICER.PROTEOSTASIS THERAPEUTICS INC - PO-SHUN LEE TO REMAIN A CONSULTANT FOR COMPANY.PROTEOSTASIS THERAPEUTICS INC - ANDREY BELOUS APPOINTED AS SENIOR MEDICAL DIRECTOR, JOINING FROM GALAPAGOS NV.

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

July 14 (Reuters) - Galapagos Nv <GLPG.AS>::GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION.GILEAD TO MAKE $3.95 BILLION UPFRONT PAYMENT AND $1.1 BILLION EQUITY INVESTMENT.GILEAD GAINS ACCESS TO GALAPAGOS' DIFFERENTIATED DRUG DISCOVERY PLATFORM AND CURRENT AND FUTURE PIPELINE OUTSIDE OF EUROPE.INVESTMENT ENABLES GALAPAGOS TO EXPAND AND ACCELERATE RESEARCH AND CLINICAL PROGRAMS.GALAPAGOS GAINS BROADER COMMERCIALIZATION ROLE FOR FILGOTINIB IN EUROPE AND AGREES TO SHARE EQUALLY IN FUTURE DEVELOPMENT COSTS.GILEAD AGREES TO 10-YEAR STANDSTILL.GILEAD SCIENCES AND GALAPAGOS ENTERED INTO A 10-YEAR GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION.GALAPAGOS WILL USE PROCEEDS TO EXPAND AND ACCELERATE ITS RESEARCH AND DEVELOPMENT PROGRAMS.GILEAD AND GALAPAGOS HAVE AGREED TO AMEND CERTAIN TERMS IN AGREEMENT GOVERNING FILGOTINIB.CO TO HAVE GREATER INVOLVEMENT IN FILGOTINIB'S GLOBAL STRATEGY AND PARTICIPATE MORE BROADLY IN COMMERCIALIZATION OF PRODUCT IN EUROPE.GILEAD'S EQUITY INVESTMENT WILL CONSIST OF A SUBSCRIPTION FOR NEW GALAPAGOS SHARES AT A PRICE OF EUR 140.59 PER SHARE.EQUITY INVESTMENT WILL INCREASE GILEAD'S STAKE FROM APPROXIMATELY 12.3% TO 22% OF ISSUED AND OUTSTANDING SHARES IN GALAPAGOS.CO INTENDS TO SEEK SHAREHOLDER APPROVAL TO ISSUE TWO WARRANTS ALLOWING GILEAD TO FURTHER INCREASE ITS OWNERSHIP TO UP TO 29.9% OF CO.DEAL ALSO INCLUDES 10-YEAR STANDSTILL RESTRICTING GILEAD'S ABILITY TO SEEK TO ACQUIRE GALAPAGOS OR INCREASE ITS STAKE BEYOND 29.9% OF CO.

Gilead To Boost Stake In Belgian Biotech Galapagos As Part Of $5.1 Billion Deal - WSJ

July 14 (Reuters) - :GILEAD TO BOOST STAKE IN BELGIAN BIOTECH GALAPAGOS AS PART OF $5.1 BILLION DEAL - WSJ.GILEAD SCIENCES TO PAY $5.1 BILLION TO BOOST ITS STAKE IN GALAPAGOS AND GAIN RIGHTS OUTSIDE EUROPE TO GALAPAGOS'S TREATMENTS IN DEVELOPMENT - WSJ.GILEAD SCIENCES WILL INVEST $1.1 BILLION, OR €140.59 ($158.49) A SHARE, TO INCREASE ITS STAKE IN GALAPAGOS TO 22% FROM 12.3% - WSJ.

Galapagos: Gilead Plans To Submit New Drug Application For Filgotinib To FDA

July 2 (Reuters) - Galapagos NV <GLPG.AS>::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.FILGOTINIB IS AN INVESTIGATIONAL AGENT AND NOT APPROVED ANYWHERE GLOBALLY.COMPANY DISCUSSED WITH AGENCY PHASE 3 FINCH STUDIES, AS WELL AS ONGOING PHASE 2 MANTA SAFETY STUDY.AS RESULT OF THIS DISCUSSION, A PATH FORWARD HAS BEEN ESTABLISHED TO SUBMIT NDA FOR FILGOTINIB AS TREATMENT FOR RHEUMATOID ARTHRITIS IN 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up